MediGene reports additional phase II results of EndoTAG-1 for the treatment of triple receptor-negative breast cancer
In: M2 EquityBites (EQB), 2010-06-24
Zeitungsartikel
Zugriff:
M2 EQUITYBITES-24 June 2010-MediGene reports additional phase II results of EndoTAG-1 for the treatment of triple receptor-negative breast cancer(C)2010 M2 COMMUNICATIONS http://www.m2.com Biotechnology company MediGene AG (Frankfurt:NDG) (Xetra:MDG) today reported [...]
Titel: |
MediGene reports additional phase II results of EndoTAG-1 for the treatment of triple receptor-negative breast cancer
|
---|---|
Zeitschrift: | M2 EquityBites (EQB), 2010-06-24 |
Veröffentlichung: | 2010 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|